Compelling epidemiologic evidence indicates that obesity is associated with a high risk of human malignancies, including thyroid cancer. We previously demonstrated that a high fat diet (HFD) effectively induces the obese phenotype in a mouse model of aggressive follicular thyroid cancer (Thrb
INTRODUCTION
The incidence of thyroid cancer, the most common malignancy in endocrine organs, has been increasing rapidly in the past decades [1, 2] . At the same time, the rates of obesity and metabolic syndrome have also risen. Recent epidemiologic studies have shown a positive association of obesity with thyroid cancer incidence [3] [4] [5] [6] . Many retrospective studies of patients with papillary thyroid cancer (PTC) show that a higher body mass index is correlated with a more aggressive PTC phenotype, such as increased tumor size, extrathyroidal invasion, and advanced tumor, node, metastasis (TNM) stage independent of age, sex, and other confounding factors [7] . These compelling epidemiologic data on the positive correlation of obesity with the risk of thyroid cancer prompted us to explore the molecular basis underpinning such a correlation.
We used a mouse model of follicular thyroid cancer (Thrb and haplo insufficiency in the Pten gene (phosphatase and tensin homologue deleted from chromosome 10) [8] . We fed Thrb PV/PV Pten +/− mice a high fat diet (HFD) to induce obesity marked by increased body weight, enlarged fat cells, and elevated serum leptin levels [9] . Biochemical and histopathologic analyses showed that the obese Thrb PV/ PV Pten +/− mice exhibit more aggressive tumor progression with increased tumor cell proliferation, shortened survival, and frequent occurrence of anaplasia [9] . Moreover, we also identified leptin-JAK2-STAT3 signaling as one pathway that mediates the obesity-induced aggressive tumor progression. Thus, these findings not only provide direct molecular evidence to support the link between obesity and thyroid cancer risk, but also open the possibility of using Thrb PV/PV Pten +/− mice to test potential molecular targets for treatment of obesity-induced thyroid cancer.
More recently, we treated Thrb
mice with a STAT3-specific inhibitor, S3I-201, aiming to block the STAT3-downstream signaling to delay obesity-exacerbated thyroid cancer progression [10] . We found that S3I-201 effectively inhibits HFD-induced aberrant activation of STAT3 and its downstream targets to markedly inhibit thyroid tumor growth and prolong survival. S3I-201 also acts to decrease expression of the key regulators of the epithelial-mesenchymal-transition, i.e., vimentin and matrix metallo proteinases, to block anaplasia and lung metastasis [10] . Thus, using HFD-Thrb
mice, we have shown that inhibition of the STAT3 activity would be a novel treatment strategy for obesity-induced thyroid cancer.
With the availability of HFD-Thrb
PV/PV
Pten +/− mice as a preclinical mouse model, we expanded the search for other potential treatment modalities for obesityinduced thyroid cancer. We considered metformin (1,1-dimethylbiguanide hydrochloride), the most widely used antihyperglycemic drug for treatment of type II diabetes patient sowing to its effectiveness, safety profile, and affordability [11, 12] . In addition to its anti-diabetic effect, epidemiologic evidence suggests that metformin may lower cancer risk, increase healthy life span and improve outcomes among diabetic patients [13] [14] [15] [16] [17] [18] [19] . Numerous studies have shown that metformin could reduce the risk of developing solid tumors [20] , such as colorectal, liver, pancreatic, stomach, breast, and thyroid cancer [20] [21] [22] [23] [24] . Recently, several studies have reported that metformin inhibits cell proliferation in thyroid cancer cells including medullary, anaplastic, and PTC cell lines [20, [25] [26] [27] . Still lacking, however, is direct molecular evidence to demonstrate the effectiveness of metformin in the treatment of obesity-induced thyroid cancer in vivo. In the present studies, we treated HFD-Thrb PV/PV Pten +/− mice with metformin and evaluated its effects on survival, tumor growth, tumor cell invasion, and occurrence of anaplasia. We found that metformin markedly decreased occurrence of capsular invasion and completely blocked vascular invasion and anaplasia in HFD-Thrb
These results suggest that metformin could be beneficial for patients with obesity-activated thyroid cancer. mice promoted thyroid carcinogenesis by reducing survival rate, increasing tumor growth, and advancing tumor stages [9] . To evaluate the effect of metformin on obesity-activated thyroid carcinogenesis, we analyzed survival, body weight, and thyroid weight in low fat diet (LFD)-or HFD-Thrb Figure 1B-a) . We next evaluated the effect of metformin on thyroid tumor growth. As reported previously [9] , the thyroid weight of HFD-Thrb Leptin mediates its effects not only via STAT3, but also via extracellular signal-regulated kinase (ERK) [28] . We therefore evaluated the activity of ERK by examining p-ERK protein levels. HFD elevated p-ERK (T202/204) without significant changes in total ERK protein levels ( Figure cell motility, and migration. We first examined whether vimentin protein levels were affected by metformin. Vimentin is a type III intermediate filament protein and is a major cytoskeletal component in mesenchymal cells. Vimentin is often used as a marker for cells undergoing epithelial-mesenchymal-transition (EMT) during metastatic progression. Vimentin is positively regulated by STAT3 [29, 30] . Moreover, biochemical analyses demonstrated direct interaction of vimentin with ERK, which promoted ERK activation and enhanced vimentin transcription [31, 32] . In line with these findings, we found that elevated vimentin in thyroid tumors of HFDThrb mice. Fibronectin (FN) is a high molecular weight protein of the extracellular matrix that binds to membrane-spanning receptor proteins, known as integrins. FN plays a major role in cell adhesion, migration, and metastasis [33, 34] . Recent studies suggest that metformin treatment could reduce tumor cell invasion in pancreatic cancer [35] . Metformin treatment of diabetetic patients is associated with low recurrence of cervical lymph node metastasis of differentiated thyroid cancer [36] . Indeed, we found that FN protein abundance was higher in thyroid tumors of HFD-Thrb Increased integrin expression levels contribute to earlier metastatic potential of thyroid cancer [37] . For example, integrin α6 has been reported to mediate progression of papillary thyroid cancer [38] . Therefore, we further evaluated the protein levels of FN receptors such as integrins α6, β1, and β3 in thyroid tumors of LFDor HFD-Thrb mice with metformin for 20 weeks had no effect on the survival or the thyroid tumor growth of these mice. Remarkably, however, the treatment reduced the occurrence of capsular invasion and abrogated the development of vascular invasion and anaplasia. Since the endpoint of metformin treatment was 20 weeks, which did not allow sufficient time for metastasis to occur, we were unable to evaluate the effect of metformin on the development of metastasis. Using molecular and biochemical analyses, we found that metformin attenuated the activity of STAT3-ERK-vimentin and FN-integrin signaling to reduce the occurrence of capsular invasion and blocked vascular invasion and anaplasia. However, the altered FN-integrin signaling may not be the only pathway that led to the reduced tumor cell invasion by metformin. We found that metformin also suppressed the occurrence of thyroid tumor cell invasion in LFD-treated Thrb PV/PV Pten +/− mice, but no changes in the FN-integrin signaling. These observations suggested that there were additional pathways affected by metformin that could reduce the tumor cells invasion. The identification of such pathways would await future studies.
RESULTS

Metformin delays thyroid tumor progression in
The findings that metformin blocked vascular invasion of thyroid tumors of Thrb PV/PV Pten +/− mice are in line with the reports in which the anti-angiogenic effects of metformin were described in colon cancer [39] , HER2+ tumor cells [40] and breast tumors [41, 42] . In colon cancer, metformin was shown to down regulate tumor angiogenesis and augment the antitumor effect oxaliplatin [39] . In HER2+ tumor cells, metformin treatment decreased microvessel-induced inhibition of tumor angiogenesis [40] . In breast tumors, metformin reduced tumor microvessel density and attenuated tumor angiogenesis [41, 42] . While metformin was shown to have anti-neoplastic effects in diabetic patients with differentiated thyroid cancer [25] , whether metformin has anti-angiogenic effects in thyroid cancer progression remains to be elucidated.
That metformin could block cancer cell invasion and anaplasia, but not tumor growth, suggested that the molecular pathways of anti-diabetic and anticancer actions of metformin could differ in vivo. Although the detailed molecular basis underlying the metabolic effects of metformin are not completely understood, the primary molecular mechanism mediating this effect appears to be the activation of AMP-activated protein kinase (AMPK) and the subsequent inhibition of mammalian targets of rapamycin (mTOR) [43] [44] [45] . Intriguingly, no significant changes in the AMPK-mTOR-p70 S6K and AMPK-mTOR-4EBP1 signaling pathways were detected in thyroid tumors of HFD-Thrb mice, PI3K-AKT is highly activated to drive aggressive tumor growth [8] . Knowing that AKT is also a downstream target of activated insulin signaling [46] , we speculate that highly activated AKT signaling could interfere with the AMPK signaling via cross talk such that the metformin-mediated inhibition of AMPK could be blunted in the thyroid of HFD-Thrb
mice. This conjecture raises the possibility that the effectiveness of metformin as an antiproliferative drug would depend on the genetic abnormalities and altered signaling pathways of thyroid cancer. That AMPK sensitivity to metformin inhibition could be modulated by cellular context is not without precedent. It has been shown that p53 is involved in mediating the energy-conserving response to AMPK activation and that loss of p53 heightens the metformininduced energy stress on cancer cells, implying that metformin may have increased efficacy in p53-deficient tumors like ovarian cancer [47] . In addition, recent studies showed that cancer cell lines with mutations in mitochondrial DNA genes have an increased response to metformin [48] . In line with these observations, an ongoing clinical trial is currently evaluating the effect of metformin on dosing of levothyroxine (T4) required for TSH suppression in patients with differentiated thyroid cancer (ClinicalTrials.gov; Identifier: NCT01341886). The outcome of this trial should uncover how the sensitivity of TSH response to T4 is modulated by metformin and could further support the notion that the effectiveness of metformin is subject to modulation by cellular regulators.
The present studies showed that metformin failed to exert antiproliferative effects to inhibit HFD-induced tumor growth in Thrb PV/PV Pten +/− mice. Still, metformin was effective in delaying thyroid cancer progression by reducing the frequency of capsular invasion and abrogating the development of vascular invasion and anaplasia. These findings suggest that metformin would be useful in preventing the metastatic spread of thyroid cancer. These findings also suggest that metformin would be useful as an adjuvant in combination treatment with other antiproliferative drugs. In view of metformin's safety and affordability, we would expect that clinical trials could soon be extended to test the effectiveness of metformin to treat differentiated and de-differentiated thyroid cancer. In addition to Thrb
mice, other mouse models have recently been developed to study thyroid cancer [49] [50] [51] [52] [53] [54] , and it would be possible to use different mouse models mimicking different types of thyroid cancer to assess the effectiveness of metformin in those models. Furthermore, these preclinical studies might also lead to the identification of genes that could potentially enhance metformin's effects, as well as genes that could render metformin insensitive. The findings of these proposed preclinical studies would be very helpful in the consideration of using metformin to improve the outcome of patients with thyroid cancer.
MATERIALS AND METHODS
Mice and treatment
The National Cancer Institute Animal Care and Use Committee approved the protocols for animal care and handling in the present study. Mice harboring the ThrbPV gene (Thrb PV/PV mice) were prepared via homologous recombination, and genotyping was carried out using the PCR method, as previously described [8] . Pten mice. The high fat diet (HFD) (60 % Kcal from fat) was purchased from Research Diets (New Brunswick, NJ, USA). The mice, housed in SPF (specific pathogens free) animal facility, were administrated HFD diet from the age of 6 weeks until the end of the study. Metformin (cat#M1566, Spectrum, Gardena, CA, USA) was diluted in drinking water (0.5 mg/ml) [55] , and the solution was changed weekly. They were monitored until they reached the age of 21 weeks, or they became moribund with rapid weight loss, hunched posture, and labored breathing. After the mice were euthanized, the thyroids were dissected for weighing, histologic analysis, and biochemical studies.
Histopathologic analysis
Thyroid glands, lungs and inguinal fat were dissected and fixed in 10% neutral-buffered formalin (Sigma-Aldrich, St. Louis, MO, USA) and subsequently embedded in paraffin. Five-micrometer-thick sections were prepared and stained with hematoxylin and eosin. For each animal, single random sections of thyroid were examined. For thyroids, morphologic evidence of hyperplasia, capsular invasion, and vascular invasion was routinely examined in that single section.
Immunohistochemistry (IHC) was conducted as previously described with some modifications [50] . For the antigen retrieval step, slides were heated in 0.05% citraconic anhydride solution (pH 7.4; Sigma-Aldrich, St. Louis, MO, USA) at 98°C for 60 minutes followed by treatment with rabbit anti-p-STAT3 antibody (1:100 dilution, Cell Signaling, Denver, MA, USA) and anticleaved caspase 3 antibody (dilution 1:300, cat. 9661, Cell Signaling) at 4°C overnight. The antigen signals were detected by treatment with the peroxidase substrate diaminobenzidine, followed by counterstaining with Gill's hematoxylin (Electron Microscopy Sciences, Hatfield, PA, USA). Relative positive cell ratio was quantified by using NIH IMAGE software (Image J 1.47).
Western blot analysis
Preparation of whole-cell lysates from thyroid glands has been described previously [50] . The protein sample (30 μg) was loaded and separated by SDS-PAGE. After electrophoresis, the protein was electrotransferred to a poly vinylidenedifluoride membrane (Immobilon-P; Millipore Corp., Billeria, MA, USA). The antibodies phosphorylated STAT3 (1:500 dilution), total-STAT3 (1:1,000 dilution), p-ERK (1:500 dilution), total-ERK (1:1,000 dilution), vimentin (1:1,000 dilution), and GAPDH (1:1,000 dilution) were purchased from Cell Signaling Technology (Danvers, MA, USA). Antibodies for fibronectin (1:200 dilution), integrin α6 (1:200 dilution), integrin β1 (1:200 dilution), integrin and β3 (1:200 dilution) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). The blots were stripped with Re-Blot Plus (Millipore, Billeria, MA, USA) and reprobed with rabbit polyclonal antibodies to GAPDH. www.impactjournals.com/oncotarget Band intensities were quantified by using NIH IMAGE software (Image J 1.47).
Statistical analysis
All data are expressed as mean ± standard errors, and Student's t test was used to compare continuous variables accordingly. The Kaplan-Meier method with log-rank test was used to compare survival in each treatment group. Statistical significance was set at p<0.05. GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA) was used to draw graphs.
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